RT Journal Article
SR Electronic
T1 Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers
JF Disease Models & Mechanisms
JO Dis Models Mech
FD The Company of Biologists Limited
SP 749
OP 757
DO 10.1242/dmm.025239
VO 9
IS 7
A1 Pfefferle, Adam D.
A1 Agrawal, Yash N.
A1 Koboldt, Daniel C.
A1 Kanchi, Krishna L.
A1 Herschkowitz, Jason I.
A1 Mardis, Elaine R.
A1 Rosen, Jeffrey M.
A1 Perou, Charles M.
YR 2016
UL http://dmm.biologists.org/content/9/7/749.abstract
AB Targeted therapies against basal-like breast tumors, which are typically ‘triple-negative breast cancers (TNBCs)’, remain an important unmet clinical need. Somatic TP53 mutations are the most common genetic event in basal-like breast tumors and TNBC. To identify additional drivers and possible drug targets of this subtype, a comparative study between human and murine tumors was performed by utilizing a murine Trp53-null mammary transplant tumor model. We show that two subsets of murine Trp53-null mammary transplant tumors resemble aspects of the human basal-like subtype. DNA-microarray, whole-genome and exome-based sequencing approaches were used to interrogate the secondary genetic aberrations of these tumors, which were then compared to human basal-like tumors to identify conserved somatic genetic features. DNA copy-number variation produced the largest number of conserved candidate personalized drug targets. These candidates were filtered using a DNA-RNA Pearson correlation cut-off and a requirement that the gene was deemed essential in at least 5% of human breast cancer cell lines from an RNA-mediated interference screen database. Five potential personalized drug target genes, which were spontaneously amplified loci in both murine and human basal-like tumors, were identified: Cul4a, Lamp1, Met, Pnpla6 and Tubgcp3. As a proof of concept, inhibition of Met using crizotinib caused Met-amplified murine tumors to initially undergo complete regression. This study identifies Met as a promising drug target in a subset of murine Trp53-null tumors, thus identifying a potential shared driver with a subset of human basal-like breast cancers. Our results also highlight the importance of comparative genomic studies for discovering personalized drug targets and for providing a preclinical model for further investigations of key tumor signaling pathways.